Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RENB 
Renovaro Biosciences Inc (RENB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RENB (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 64.23% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.29M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 1708051 | Beta 0.41 | 52 Weeks Range 0.40 - 2.97 | Updated Date 04/1/2025 |
52 Weeks Range 0.40 - 2.97 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.09% | Return on Equity (TTM) -188.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 95484497 | Price to Sales(TTM) - |
Enterprise Value 95484497 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.37 | Shares Outstanding 162392992 | Shares Floating 76658970 |
Shares Outstanding 162392992 | Shares Floating 76658970 | ||
Percent Insiders 50.1 | Percent Institutions 13.73 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Renovaro Biosciences Inc
Company Overview
History and Background
Renovaro Biosciences Inc., formerly known as ENGlobal Corporation, is a biotechnology company focused on cell, gene, and immunotherapy to address unmet needs in cancer and infectious diseases. It has evolved from an engineering firm to a biotech innovator, marking a significant strategic shift.
Core Business Areas
- Immunotherapy Development: Focused on developing novel immunotherapies targeting solid tumors, leveraging gene-modified cell therapies and oncolytic viruses.
Leadership and Structure
The company is led by a management team with experience in biotechnology and pharmaceutical industries. Details on specific roles and organizational charts are typically available in their SEC filings and corporate website.
Top Products and Market Share
Key Offerings
- REN001 (Oncolytic Virus Therapy): REN001 is an oncolytic virus-based immunotherapy. Clinical trials are still underway, so market share and revenue data are currently unavailable. Competitors in the oncolytic virus space include Amgen (T-VEC), BioNTech (ONC2S), and Replimune.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, particularly in the area of immuno-oncology. Significant R&D investment, regulatory hurdles, and commercialization challenges are characteristic of the industry.
Positioning
Renovaro is positioned as an innovative biotech company focused on developing novel immunotherapies. Their competitive advantage lies in the unique design of their oncolytic virus and cell therapy platform.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is estimated to be in the tens of billions of dollars annually. Renovaro's TAM is a subset of this, representing the portion addressable by their specific therapy approaches. Figures vary widely based on market analysis and projections.
Upturn SWOT Analysis
Strengths
- Innovative immunotherapy platform
- Experienced management team
- Potential for breakthrough cancer therapies
Weaknesses
- Limited clinical data
- Dependence on financing
- High R&D costs
- Relatively small company size compared to peers
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Positive regulatory approvals
Threats
- Clinical trial failures
- Competition from established players
- Regulatory setbacks
- Market volatility
- Intellectual Property challenges
Competitors and Market Share
Key Competitors
- AMGN
- BNTX
- RPiL
Competitive Landscape
Renovaro faces significant competition from established pharmaceutical companies with larger R&D budgets and more advanced clinical programs. They must demonstrate superior efficacy and safety to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the early stage of the company. Future growth depends heavily on clinical trial results and regulatory approvals.
Future Projections: Future projections are speculative and depend on analyst estimates. There are significant uncertainties.
Recent Initiatives: Focus on advancing clinical trials for REN001 and related programs.
Summary
Renovaro Biosciences is a high-risk, high-reward biotech company focused on novel cancer immunotherapies. While their innovative platform holds promise, their success is heavily contingent on positive clinical trial results and securing adequate funding. Investors should be aware of the speculative nature of this investment.
Similar Companies
- CRSP
- EDIT
- BEAM
- ZYME
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q), Company website, Press releases, Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Renovaro Biosciences Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2015-02-02 | CEO & Director Mr. David H. Weinstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://renovarogroup.com |
Full time employees 25 | Website https://renovarogroup.com | ||
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.